Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Schade

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Idrugs : the Investigational Drugs Journal|March 9, 2006
NMR fragment screening: Advantages and applicationsMarkus Schade
Current Opinion in Drug Discovery & Development|May 17, 2005
NMR fragment screening: tackling protein-protein interaction targetsMarkus Schade, Hartmut Oschkinat
Journal of Medicinal Chemistry|November 16, 2010
Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85CChristoph Scheich, Vera Puetter, Markus Schade
RSC Medicinal Chemistry|November 18, 2024
Property-based optimisation of PROTACsJames S Scott, Iacovos N Michaelides, Markus Schade
Chemical Science|August 2, 2024
Negative cooperativity in the formation of H-bond networks involving primary anilinesFergal E Hanna, Alexander J Root, Markus Schade, et al.
Plos One|December 14, 2011
Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screenChristoph Scheich, Zoltán Szabadka, Beáta Vértessy, et al.
Journal of Medicinal Chemistry|September 4, 2020
Highly Selective Sub-Nanomolar Cathepsin S Inhibitors by Merging Fragment Binders with Nitrile InhibitorsMarkus Schade, Beatrix Merla, Bernhard Lesch, et al.
Nature Reviews. Chemistry|December 13, 2025
Lessons learned in linking PROTACs from discovery to the clinicAndy Pike, Esther C Y Lee, Iacovos N Michaelides, et al.
Journal of Medicinal Chemistry|June 28, 2019
Fragment-Based Discovery of Novel Potent Sepiapterin Reductase InhibitorsJo Alen, Markus Schade, Markus Wagener, et al.
Angewandte Chemie (International Ed. in English)|May 4, 2006
Discovery of low-molecular-weight ligands for the AF6 PDZ domainMangesh Joshi, Carolyn Vargas, Prisca Boisguerin, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Idrugs : the Investigational Drugs Journal|March 9, 2006
NMR fragment screening: Advantages and applicationsMarkus Schade
Current Opinion in Drug Discovery & Development|May 17, 2005
NMR fragment screening: tackling protein-protein interaction targetsMarkus Schade, Hartmut Oschkinat
Journal of Medicinal Chemistry|November 16, 2010
Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85CChristoph Scheich, Vera Puetter, Markus Schade
RSC Medicinal Chemistry|November 18, 2024
Property-based optimisation of PROTACsJames S Scott, Iacovos N Michaelides, Markus Schade
Chemical Science|August 2, 2024
Negative cooperativity in the formation of H-bond networks involving primary anilinesFergal E Hanna, Alexander J Root, Markus Schade, et al.
Plos One|December 14, 2011
Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screenChristoph Scheich, Zoltán Szabadka, Beáta Vértessy, et al.
Journal of Medicinal Chemistry|September 4, 2020
Highly Selective Sub-Nanomolar Cathepsin S Inhibitors by Merging Fragment Binders with Nitrile InhibitorsMarkus Schade, Beatrix Merla, Bernhard Lesch, et al.
Nature Reviews. Chemistry|December 13, 2025
Lessons learned in linking PROTACs from discovery to the clinicAndy Pike, Esther C Y Lee, Iacovos N Michaelides, et al.
Journal of Medicinal Chemistry|June 28, 2019
Fragment-Based Discovery of Novel Potent Sepiapterin Reductase InhibitorsJo Alen, Markus Schade, Markus Wagener, et al.
Angewandte Chemie (International Ed. in English)|May 4, 2006
Discovery of low-molecular-weight ligands for the AF6 PDZ domainMangesh Joshi, Carolyn Vargas, Prisca Boisguerin, et al.
Pageof 3